The main purpose of this study is to measure how much of LY3437943 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to healthy participants with normal liver function. The safety and tolerability of LY3437943 will also be evaluated. The study may last up to 9 weeks for each participant including the screening period.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
43
Administered SC.
Arizona Clinical Trials - Chandler
Chandler, Arizona, United States
Accel Research Sites- Clinical Research Unit
DeLand, Florida, United States
Advanced Pharma Clinical Research
Miami, Florida, United States
American Research Corporation at Texas Liver Institute
San Antonio, Texas, United States
Pharmacokinetics (PK): Area under the concentration versus time curve from time zero to infinity (AUC0-∞) of LY3437943
PK: AUC0-∞ of LY3437943
Time frame: Predose up to 30 days postdose
PK: Maximum observed concentration (Cmax) of LY3437943
PK: Cmax of LY3437943
Time frame: Predose up to 30 days postdose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pinnacle Clinical Research
San Antonio, Texas, United States